[ad_1]
LONDON – AstraZeneca PLC said it would update and republish efficacy data from human trials of its Covid-19 vaccine later this week after U.S. officials made the unusual decision to publicly question its accuracy, the latest step in fake of the British drug giant as he fights his shot into American arms.
In an early morning statement, the National Institute of Allergy and Infectious Diseases said it had been informed by the independent data monitoring board working with AstraZeneca on the U.S. trials that the drug company may have used outdated information. in your audience. dissemination of the efficacy of the vaccine. The day before, AstraZeneca released interim data from a large-scale trial in the US that it said found its Covid-19 vaccine to be 79% effective in preventing symptomatic illness.
The results served as a brief vote of confidence in the injection, which has been clouded by uncertainty about previous confusing efficiency results and large-scale production issues. More recently, reported cases of rare blood clotting in Europe raised concerns about the safety of the vaccine, although European regulators have recommended its continued use. The US trials showed no link between clotting and the vaccine, and Tuesday’s NIAID statement raised no questions about that finding or other safety-related concerns.
Nationwide, the seven-day average of new coronavirus cases dropped slightly, to 53,441. Texas said it plans to expand vaccine eligibility to all adults starting next week, joining several states that have repealed the restrictions.
As of Tuesday, 17.6% of Americans 18 and older were fully vaccinated, according to the Centers for Disease Control and Prevention.
